

Case Study Presentation: Biocon's Biotechnology Innovation



BY:

JAGRITI CHHABRA

Scientific
Report
Template

01



CONTENTS

Title Slide



Part 1



Introduction



Part 2



**The
Innovation –
Biosimilar
Insulin**

Part 3



**Novel
Biologics
Portfolio**

Part 4



contents



part 5
Applications

part 6
Market Impact

part 7
Competitive Advantage

part 8
Challenges

part 9
SWOT Analysis

part 10
Future Outlook

Title Slide

- *Biocon's Biotechnology Innovation: Biosimilars & Biologics*
- *Subtitle: Affordable Access to Advanced Therapies*
- *Your name / course / date*



01

01

Introduction

- BIOCON: INDIA'S LARGEST BIOPHARMACEUTICAL COMPANY
- FOCUS ON BIOSIMILARS, BIOLOGICS, GENERICS
- INNOVATION: AFFORDABLE INSULIN & MONOCLONAL ANTIBODIES



02

02

The Innovation

- Biosimilar Insulin

- BIOCON DEVELOPED BIOSIMILAR INSULINS (INSULIN GLARGINE, INSULIN ASPART)**
- FIRST INDIAN COMPANY TO GET US FDA APPROVAL FOR BIOSIMILAR INSULIN**
- ENABLES AFFORDABLE DIABETES CARE GLOBALLY**



03

03

Novel Biologics Portfolio

- ONCOLOGY: TRASTUZUMAB (BIOSIMILAR TO HERCEPTIN)
- IMMUNOLOGY: ADALIMUMAB BIOSIMILAR
- DIABETES: GLP-1 PEPTIDE GENERICS
- DIFFERENTIATED OFFERING ACROSS ONCOLOGY , IMMUNOLOGY , DIABETES



04

04

Applications

“

**- Diabetes
care**

- Immunology

**- Cancer
treatment**

**- Global
healthcare**



Market Impact



- 1. Biosimilar insulins & GLP-1 peptides**
- 2. Expanded presence in US, EU, Japan**

3. Revenue from biosimilars contributes ~45% of Biocon's total

Competitive Advantage



- ▶ Cost-effective R&D in India.
- ▶ Strategic partnership.
- ▶ Strong regulatory track record.



121+

*MYLAN,
VIATRIS*

131+

PFIZER

121+

*FDA, EMA
APPROVALS*

Challenges

1. - Regulatory hurdles.

2. - Pricing pressures.



3. - Patent litigation.

4. - High R&D costs.

SWOT Analysis

Strengths:

Affordable innovation, global partnerships



Opportunities:

Personalized medicine, cell therapies



Weaknesses:

Reliance on biosimilars, regulatory delays



Biocon is well-positioned as a global biosimilars leader with strong R&D and partnerships, but faces challenges from debt, competition, and regulatory hurdles. Its future growth depends on successful integration of acquisitions and expansion into new therapeutic areas.

Founder-led vision:

Kiran Mazumdar-Shaw's leadership has built credibility and brand recognition worldwide.



Threats:

Competition from Amgen, Roche, Moderna




Future Outlook

- Expansion into novel biologics & cell therapies




- Strengthening oncology & diabetes portfolio




- Aim: Become top 10 global biotech firm


Case Study Highlight



- Biocon's biosimilar insulin reduced treatment cost by 30-40% compared to branded versions




- Impact: Millions of patients in India, US, EU gained access to affordable diabetes care



Conclusion



- Biocon's innovation in biosimilars & biologics transformed global healthcare
 - Applications: Diabetes, cancer, immunology
 - Market impact: Affordable access, global expansion
 - Challenges: Regulation, competition, pricing
 - Future: Novel biologics, cell therapies, global leadership



THANKS FOR WATCHING



by:

JAGRITI CHHABRA

01